Liu Jiao, Kang Rui, Tang Daolin
DAMP Laboratory, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510150, China.
Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Trends Cancer. 2025 Jan;11(1):4-5. doi: 10.1016/j.trecan.2024.11.004. Epub 2024 Dec 2.
Autophagy has a dual role in tumor progression and therapy, influenced by specific receptors and cargo selection. Recent research published in Cell by Herhaus et al. identifies immunity-related GTPase Q (IRGQ) as a novel autophagy receptor that facilitates immune evasion in hepatocellular carcinoma (HCC) by degrading histocompatibility complex class I (MHC-I) molecules, highlighting a potential target to enhance immunotherapy.
自噬在肿瘤进展和治疗中具有双重作用，受特定受体和货物选择的影响。Herhaus等人最近发表在《细胞》杂志上的研究将免疫相关GTP酶Q（IRGQ）鉴定为一种新型自噬受体，它通过降解I类组织相容性复合体（MHC-I）分子促进肝细胞癌（HCC）的免疫逃逸，突出了一个增强免疫治疗的潜在靶点。
